1. A method for preventing andor treating a degenerative disorder of the central nervous system in a patient at risk for developing or diagnosed with the same, which comprises administering to the patient in need thereof an effective amount of a therapeutic agent which is 5-(fluoromethyl)piperidine-3,4-diol, 5-(chloromethyl)piperidine-3,4-diol, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, or any combination of two or more thereof.
2. The method of claim 1, which comprises administering 5-(fluoromethyl)piperidine-3,4-diol or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
3. The method of claim 1, which comprises administering (3R,4R,5R)-5-(fluoromethyl)piperidine-3,4-diol or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
4. The method of claim 1, which comprises administering (3R,4R,5R)-5-(fluoromethyl)piperidine-3,4-diol hydrochloride.
5. The method of claim 1, which comprises administering 5-(chloromethyl)piperidine-3,4-diol or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
6. The method of claim 1, which comprises administering (3R,4R,5S)-5-(chloromethyl)piperidine-3,4-diol or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
7. The method of claim 1, which comprises administering (3R,4R,5S)-5-(chloromethyl)piperidine-3,4-diol.
8. The method of claim 1, wherein the degenerative disorder is a synucleinopathy.
9. The method of claim 1, wherein the degenerative disorder is characterized by Lewy bodies.
10. The method of claim 1, wherein the degenerative disorder is Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy or Alzheimer’s disease.
12. The method of claim 1, wherein the degenerative disorder is associated with aggregation of at least one protein.
13. The method of claim 1, wherein the degenerative disorder is associated with aggregation of alpha-synuclein.
14. The method of claim 1, wherein the degenerative disorder is associated with aggregation of non-Abeta component.
15. The method of claim 1, wherein the degenerative disorder is associated with accumulation of at least one glycolipid.
16. The method of claim 1, wherein the degenerative disorder is associated with accumulation of at least one glycosphingolipid.
17. The method of claim 1, wherein the degenerative disorder is associated with accumulation of glucocerebroside.
18. The method of claim 1, wherein the degenerative disorder is associated with a mutation in glucocerebrosidase.
19. The method of claim 1, further comprising administering an effective amount of at least one other therapeutic agent.
20. The method of claim 19, wherein at least one other therapeutic agent is levodopa, an anticholinergic, a catechol-O-methyl transferase inhibitor, a dopamine receptor agonist, a monoamine oxidase inhibitor, a peripheral decarboxylase inhibitor, or an anti-inflammatory agent.
21. A method for preventing andor treating Parkinson’s disease in a patient at risk for developing or diagnosed with the same, which comprises administering to the patient in need thereof an effective amount of (3R,4R,5R)-5-(fluoromethyl)piperidine-3,4-diol, (3R,4R,5S)-5-(chloromethyl)piperidine-3,4-diol, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, or any combination of two or more thereof.
22. The method of claim 21, which comprises administering (3R,4R,5R)-5-(fluoromethyl)piperidine-3,4-diol or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
23. The method of claim 21, which comprises administering (3R,4R,5R)-5-(fluoromethyl)piperidine-3,4-diol hydrochloride.
24. The method of claim 21, which comprises administering (3R,4R,5S)-5-(chloromethyl)piperidine-3,4-diol or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
25. The method of claim 21, which comprises administering (3R,4R,5S)-5-(chloromethyl)piperidine-3,4-diol.
26. The method of claim 21, further comprising administering an effective amount of at least one other therapeutic agent.
27. The method of claim 26, wherein at least one other therapeutic agent is levodopa, an anticholinergic, a catechol-O-methyl transferase inhibitor, a dopamine receptor agonist, a monoamine oxidase inhibitor, a peripheral decarboxylase inhibitor, or an anti-inflammatory agent.
28. A kit comprising:
a container having an effective amount of 5-(fluoromethyl)piperidine-3,4-diol, 5-(chloromethyl)piperidine-3,4-diol, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, or any combination of two or more thereof;
instructions for using the same to prevent andor treat a degenerative disorder of the central nervous system.
29. The kit of claim 28, wherein the degenerative disorder of the central nervous system is Parkinson’s disease.
30. The kit of claim 28, wherein the degenerative disorder of the central nervous system is Alzheimer’s disease.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A controller driver, comprising:
a timing control circuit, outputting a plurality of control signals;
a data memory unit, storing image data;
a data selection unit, coupled to the data memory unit, and selecting to output the image data provided by the data memory unit as display data, or generating the display data according to a command or a test pattern provided from an external processor; and
a data line driving circuit, coupled to the timing control circuit and the data selection unit, receiving the display data from the data selection unit, and outputting a grayscale voltage according to the control signals.
2. The controller driver as claimed in claim 1, wherein the data selection unit directly transmits the image data outputted by the data memory unit to the data line driving circuit to serve as the display data when the controller driver is operated in a normal operation mode, and the data selection unit generates the display data to the data line driving circuit according to the command or the test pattern provided by the external processor when the controller driver is operated in a test operation mode.
3. The controller driver as claimed in claim 2, wherein when the controller driver is operated in the test operation mode, the data selection unit provides the test pattern outputted by the external processor to the data line driving circuit to serve as the display data.
4. The controller driver as claimed in claim 2, wherein when the controller driver is operated in the test operation mode, the data selection unit generates a corresponding test pattern to the data line driving circuit to serve as the display data according to the command outputted by the external processor.
5. The controller driver as claimed in claim 2, wherein when the controller driver is operated in the test operation mode, the data selection unit decodes the command and selectively provides the test pattern to a part of or all of channels of the data line driving circuit to serve as the display data according to a decoding result.
6. The controller driver as claimed in claim 1, wherein the data selection unit comprises:
a plurality of logic units, each having an output terminal connected to one of a plurality of output stage circuits of the data line driving circuit,
wherein the logic units select to output the image data provided by the data memory unit to the output stage circuits, or generate the display data to the output stage circuits according to the command or the test pattern provided by the external processor.
7. The controller driver as claimed in claim 1, further comprising:
a system interface circuit, coupled to the data memory unit, the data selection unit and the timing control circuit,
wherein the external processor transmits the command or the test pattern to the data selection unit through the system interface circuit.
8. The controller driver as claimed in claim 1, wherein the data memory unit comprises:
an image data memory, storing the image data; and
a memory control circuit, coupled between the image data memory and the data selection unit.